data_1ju5_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1ju5 _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 120.786 0.327 . . . . 0.0 111.168 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.48 ' CE3' HD12 ' A' ' 101' ' ' LEU . 28.6 p-90 -92.53 -18.71 22.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.271 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . 0.472 ' CE1' ' OH ' ' A' ' 47' ' ' TYR . 2.7 t80 -83.4 96.0 8.41 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.864 0.364 . . . . 0.0 111.098 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' TRP . . . . . 0.478 ' CE3' HD12 ' A' ' 18' ' ' LEU . 39.1 m95 -100.58 110.04 22.16 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.629 179.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -98.67 132.96 11.13 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.635 -0.793 . . . . 0.0 112.749 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 73.75 26.06 1.9 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.785 0.326 . . . . 0.0 111.089 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.478 HD12 ' CE3' ' A' ' 15' ' ' TRP . 4.4 tp -81.56 115.04 20.67 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.933 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.07 146.3 53.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.913 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . 0.437 ' HD3' ' P ' ' B' ' 221' ' ' PTR . 22.6 mtm180 -55.06 -50.92 67.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.853 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 -56.75 -32.13 65.27 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.883 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -69.83 -52.38 25.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.798 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -49.8 -56.22 11.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.013 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.8 t -56.1 -45.62 80.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.029 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -61.18 -21.28 63.65 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.428 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 30.1 mt -91.97 -43.47 9.43 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.971 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.424 HD21 ' N ' ' A' ' 52' ' ' SER . 7.5 mp -78.95 -23.51 44.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.995 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 1.7 tp60 -50.31 119.21 3.51 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.872 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.76 10.22 86.37 Favored Glycine 0 CA--C 1.52 0.381 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.911 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 85.3 mm-40 -90.48 129.23 36.67 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 121.067 0.46 . . . . 0.0 111.029 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.42 ' CD ' ' O ' ' A' ' 32' ' ' HIS . 0.0 OUTLIER -49.28 164.49 0.08 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.728 179.736 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' HIS . . . . . 0.42 ' O ' ' CD ' ' A' ' 31' ' ' ARG . 3.7 m170 -69.02 148.16 50.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.953 0.406 . . . . 0.0 111.262 -179.435 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 110.04 -18.51 28.58 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.535 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.425 ' CG1' ' HB3' ' A' ' 52' ' ' SER . 14.9 p -80.06 123.79 37.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.787 0.327 . . . . 0.0 111.138 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.509 ' CG ' ' CD2' ' A' ' 114' ' ' LEU . 42.1 p90 -147.15 157.99 43.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.962 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.434 ' CD2' HG11 ' A' ' 118' ' ' VAL . 2.4 pp -165.31 150.55 9.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.022 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.451 HG22 ' CD1' ' A' ' 47' ' ' TYR . 10.5 p -91.49 147.04 5.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.833 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.436 ' N ' HG21 ' A' ' 37' ' ' VAL . 41.8 ptt85 -152.55 147.43 26.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.019 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -70.74 129.5 39.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.829 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.0 t -63.94 152.27 40.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.895 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 50.8 m -85.01 -50.05 7.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.023 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 9.1 t -94.39 23.97 4.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.209 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -146.48 97.78 4.31 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.847 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.54 136.7 43.77 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.537 2.158 . . . . 0.0 112.292 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 60.56 33.68 82.81 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.439 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -129.02 132.94 47.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.814 0.34 . . . . 0.0 110.941 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.523 ' CE2' ' CD1' ' A' ' 97' ' ' LEU . 9.7 m-85 -92.56 168.32 11.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.803 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.424 ' CG1' ' O ' ' A' ' 60' ' ' TYR . 4.0 t -143.58 135.43 23.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.031 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.466 ' HG ' ' CE2' ' A' ' 104' ' ' TYR . 1.1 mm? -92.02 112.13 23.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.898 -179.82 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -94.51 138.32 32.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.793 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.1 m -151.37 121.36 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.08 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.425 ' HB3' ' CG1' ' A' ' 34' ' ' VAL . 15.8 t -77.4 97.31 4.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.0 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.419 ' CG ' ' OG1' ' A' ' 111' ' ' THR . 0.0 OUTLIER -75.02 -160.31 0.11 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.834 179.844 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.416 ' O ' ' CB ' ' A' ' 55' ' ' SER . 7.0 p-10 -77.47 81.29 3.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.87 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.416 ' CB ' ' O ' ' A' ' 54' ' ' ASN . 0.7 OUTLIER 80.47 14.86 0.75 Allowed 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.326 -179.974 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -151.8 128.33 10.73 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.784 0.326 . . . . 0.0 110.765 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.402 ' O ' ' CG1' ' A' ' 57' ' ' VAL . 14.1 p -95.97 113.28 29.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.239 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -87.66 160.28 18.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.76 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' HIS . . . . . . . . . . . . . 3.1 p80 -147.83 104.82 3.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.233 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.476 ' CE2' ' CD2' ' A' ' 109' ' ' LEU . 95.3 m-85 -86.42 145.21 26.94 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.453 179.539 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.429 ' HB ' ' CG ' ' B' ' 221' ' ' PTR . 2.3 tt -86.31 133.85 28.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.906 0.384 . . . . 0.0 111.613 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.43 HD11 ' N ' ' A' ' 62' ' ' ILE . 5.2 mp -130.99 150.13 34.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.91 179.741 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -104.19 140.26 38.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.873 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.61 146.11 32.13 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.019 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 16.7 p -59.38 151.21 24.23 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.065 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -76.17 -85.38 0.38 Allowed Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.915 -0.659 . . . . 0.0 112.737 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.525 ' HG2' ' CG ' ' C' ' 99' ' ' TRP . 35.1 Cg_exo -57.76 164.17 8.12 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.583 2.189 . . . . 0.0 112.279 179.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.51 ' N ' ' CD ' ' A' ' 69' ' ' PRO . 0.0 OUTLIER -70.38 -46.99 19.78 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.104 178.867 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.51 ' CD ' ' N ' ' A' ' 68' ' ' ARG . 28.5 Cg_exo -58.21 136.36 74.18 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 122.323 2.015 . . . . 0.0 112.124 179.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -83.37 128.74 4.9 Favored 'Trans proline' 0 N--CA 1.453 -0.888 0 C-N-CA 122.153 1.902 . . . . 0.0 109.895 178.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.431 ' CG2' ' HB3' ' C' ' 112' ' ' PRO . 1.5 p -72.11 128.92 88.48 Favored Pre-proline 0 C--N 1.323 -0.544 0 C-N-CA 120.177 -0.609 . . . . 0.0 111.342 -178.706 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.481 ' HG2' ' CE1' ' C' ' 115' ' ' TYR . 11.7 Cg_endo -82.91 163.17 15.88 Favored 'Trans proline' 0 N--CA 1.455 -0.772 0 C-N-CA 122.345 2.03 . . . . 0.0 112.492 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -78.84 169.06 20.06 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.737 2.291 . . . . 0.0 112.597 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -95.43 169.1 9.78 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.833 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -49.77 164.09 0.43 Allowed 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.658 2.238 . . . . 0.0 112.33 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -53.24 -22.45 6.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.316 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 -69.74 174.6 2.94 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.642 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -48.52 122.32 7.66 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.388 2.059 . . . . 0.0 112.173 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -86.6 118.69 1.57 Allowed 'Trans proline' 0 N--CA 1.461 -0.441 0 C-N-CA 122.638 2.225 . . . . 0.0 112.51 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.29 128.8 10.73 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.421 2.08 . . . . 0.0 112.251 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 48.31 46.93 28.37 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.579 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 13.5 p -63.06 117.18 3.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.891 0.376 . . . . 0.0 111.175 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 48.3 t -151.1 89.59 4.25 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.88 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.67 158.1 8.77 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.619 2.213 . . . . 0.0 112.326 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 13.1 m -96.58 1.2 51.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.712 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 1.4 mtt85 -52.06 169.06 0.08 Allowed 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.808 0.337 . . . . 0.0 110.918 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -84.64 148.38 26.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.642 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -144.17 140.4 29.33 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.049 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.43 HG23 ' CD1' ' A' ' 100' ' ' LEU . 4.2 tp -156.99 115.89 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.975 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 59.95 -134.77 50.82 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.503 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 8.1 t0 -89.94 24.33 2.46 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 111.649 0.24 . . . . 0.0 111.649 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.0 150.62 30.19 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.874 0.369 . . . . 0.0 111.148 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.428 ' C ' ' CD1' ' A' ' 94' ' ' PHE . 2.2 mt-10 -112.95 167.12 10.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.73 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . 0.482 ' CD1' HD21 ' A' ' 100' ' ' LEU . 39.2 m-85 -146.96 166.13 27.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.056 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 27.4 t0 -75.07 -34.33 61.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.377 -179.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.424 ' CB ' ' HD2' ' A' ' 98' ' ' PRO . 35.0 t -166.83 -173.41 2.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.961 0.41 . . . . 0.0 111.303 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.523 ' CD1' ' CE2' ' A' ' 47' ' ' TYR . 0.6 OUTLIER -61.13 -48.35 92.28 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.17 -179.885 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.47 ' CD ' ' N ' ' A' ' 97' ' ' LEU . 71.1 Cg_exo -45.75 -49.61 10.63 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.245 1.963 . . . . 0.0 111.873 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -65.99 -38.82 89.49 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.576 179.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.482 HD21 ' CD1' ' A' ' 94' ' ' PHE . 0.0 OUTLIER -59.68 -60.46 3.8 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.999 179.59 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.48 HD12 ' CE3' ' A' ' 13' ' ' TRP . 16.2 mt -48.17 -44.02 32.13 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.964 179.531 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.422 ' O ' ' CD1' ' A' ' 106' ' ' ILE . 4.6 mt-10 -58.05 -41.7 83.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.623 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.48 ' HB2' ' CE2' ' A' ' 94' ' ' PHE . 14.2 t80 -58.24 -53.48 57.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.81 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . 0.48 ' CE2' HD22 ' A' ' 109' ' ' LEU . 3.0 m-85 -56.38 -32.85 65.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.821 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 4.5 ttpm? -77.32 -27.34 52.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.946 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.422 ' CD1' ' O ' ' A' ' 102' ' ' GLU . 5.3 mt -93.96 -21.81 5.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.388 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 9.1 t60 -96.02 173.83 7.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.885 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -108.61 45.86 1.0 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.952 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.48 HD22 ' CE2' ' A' ' 104' ' ' TYR . 0.3 OUTLIER -55.24 -69.41 0.13 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.648 179.867 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 16.1 p-10 -102.32 -176.95 3.26 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.466 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' THR . . . . . 0.431 ' O ' ' CG2' ' A' ' 112' ' ' THR . 18.2 m -46.64 125.05 6.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.028 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' THR . . . . . 0.431 ' CG2' ' O ' ' A' ' 111' ' ' THR . 12.5 t 47.45 -176.15 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.201 -179.409 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -97.23 159.96 14.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.123 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.509 ' CD2' ' CG ' ' A' ' 35' ' ' PHE . 5.8 mp -72.43 155.96 39.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.732 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 58.8 mt -114.23 -64.25 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.213 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -150.64 160.06 33.28 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.989 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.99 159.01 54.76 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.583 2.189 . . . . 0.0 112.306 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.434 HG11 ' CD2' ' A' ' 36' ' ' LEU . 17.1 m -49.9 -29.92 5.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.143 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -79.03 -179.12 6.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.919 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 7.9 mtm180 . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.27 -0.871 . . . . 0.0 110.894 179.997 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . 0.47 ' CB ' ' CD ' ' B' ' 218' ' ' PRO . 4.4 mp0 . . . . . 0 N--CA 1.487 1.424 0 CA-C-O 120.68 0.276 . . . . 0.0 111.225 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 218' ' ' PRO . . . . . 0.47 ' CD ' ' CB ' ' B' ' 217' ' ' GLU . 67.3 Cg_endo -74.35 63.25 5.37 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.591 2.194 . . . . 0.0 112.327 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 219' ' ' GLY . . . . . . . . . . . . . . . -128.14 59.8 0.68 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.485 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 220' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -70.89 -32.44 13.88 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.578 2.186 . . . . 0.0 112.332 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 221' ' ' PTR . . . . . 0.437 ' P ' ' HD3' ' A' ' 20' ' ' ARG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 222' ' ' ALA . . . . . . . . . . . . . . . -74.59 -61.54 1.84 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.143 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 223' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 69.82 95.24 0.05 OUTLIER Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.893 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 224' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -69.16 105.21 1.35 Allowed 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.566 2.177 . . . . 0.0 112.319 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 225' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -133.71 -46.51 0.8 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.904 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 226' ' ' VAL . . . . . . . . . . . . . 43.1 t 53.63 71.3 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.145 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 227' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -138.22 -74.76 0.39 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.905 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 12.1 p 53.34 -170.68 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.136 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 229' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.226 -0.893 . . . . 0.0 110.877 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 62' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.762 0.315 . . . . 0.0 111.204 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 63' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_exo -51.9 -39.62 68.28 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.559 2.173 . . . . 0.0 112.284 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 64' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -176.91 40.61 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.924 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 65' ' ' LEU . . . . . . . . . . . . . 4.8 tp -121.25 108.34 13.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.855 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 66' ' ' PHE . . . . . 0.48 ' CD1' ' HB ' ' C' ' 90' ' ' VAL . 29.4 m-85 -133.79 176.62 8.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 67' ' ' VAL . . . . . 0.43 HG21 ' N ' ' C' ' 68' ' ' ALA . 14.9 p -154.32 143.14 13.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.301 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 68' ' ' ALA . . . . . 0.43 ' N ' HG21 ' C' ' 67' ' ' VAL . . . -86.12 137.07 32.94 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.041 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 69' ' ' LEU . . . . . 0.464 ' CD1' ' CG2' ' C' ' 117' ' ' THR . 4.3 mp -85.53 -29.77 23.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.957 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 70' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -128.95 174.04 9.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.788 -179.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 71' ' ' ASP . . . . . 0.414 ' N ' ' HB3' ' C' ' 84' ' ' LYS . 9.6 p-10 -89.36 109.8 20.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.903 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 72' ' ' PHE . . . . . 0.418 ' HB3' ' CG1' ' C' ' 82' ' ' ILE . 25.6 t80 -96.06 141.75 29.08 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.885 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 73' ' ' VAL . . . . . . . . . . . . . 56.1 t -118.63 134.58 61.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.144 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 74' ' ' ALA . . . . . . . . . . . . . . . -118.98 147.93 43.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.067 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 75' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -98.22 26.97 4.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.944 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 76' ' ' GLY . . . . . . . . . . . . . . . 92.56 -25.02 20.45 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.512 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 77' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -57.31 -161.8 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.811 0.339 . . . . 0.0 110.859 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 78' ' ' ASN . . . . . 0.493 ' HB3' ' CD1' ' C' ' 110' ' ' TRP . 0.3 OUTLIER -50.39 -26.85 5.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.881 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' C' C ' 79' ' ' THR . . . . . 0.43 HG23 ' CB ' ' A' ' 69' ' ' PRO . 0.6 OUTLIER -75.49 163.4 27.43 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.646 -179.963 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' C' C ' 80' ' ' LEU . . . . . 0.415 ' CB ' ' HA3' ' C' ' 109' ' ' GLY . 1.9 tp -135.22 119.36 17.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.668 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 81' ' ' SER . . . . . . . . . . . . . 49.1 p -55.02 114.87 1.92 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.061 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 82' ' ' ILE . . . . . 0.418 ' CG1' ' HB3' ' C' ' 72' ' ' PHE . 5.9 pt -134.32 150.52 30.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.157 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 83' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -89.15 -179.62 5.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.181 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 84' ' ' LYS . . . . . 0.414 ' HB3' ' N ' ' C' ' 71' ' ' ASP . 7.7 ptpp? -91.1 149.91 21.61 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.968 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 85' ' ' GLY . . . . . . . . . . . . . . . 71.48 12.23 73.06 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.94 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 86' ' ' GLU . . . . . 0.419 ' O ' ' CG2' ' C' ' 67' ' ' VAL . 3.7 tp10 -91.04 145.01 25.05 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.8 0.334 . . . . 0.0 110.837 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 87' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -93.98 125.7 38.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.809 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -128.41 154.63 45.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.957 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 89' ' ' ARG . . . . . . . . . . . . . 2.5 mtt-85 -96.85 101.94 13.62 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.739 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 90' ' ' VAL . . . . . 0.48 ' HB ' ' CD1' ' C' ' 66' ' ' PHE . 57.1 t -84.48 107.57 15.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.3 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 91' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -118.74 19.06 13.27 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.083 179.77 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 92' ' ' GLY . . . . . . . . . . . . . . . -155.18 141.2 7.92 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.676 -0.774 . . . . 0.0 112.524 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 93' ' ' TYR . . . . . . . . . . . . . 59.2 m-85 -131.34 173.12 11.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.808 0.337 . . . . 0.0 110.925 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 94' ' ' ASN . . . . . . . . . . . . . 20.0 t-20 -98.75 164.88 12.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.912 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 95' ' ' HIS . . . . . . . . . . . . . 81.9 t60 -67.63 -25.23 65.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.94 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 96' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -103.44 -15.3 15.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.379 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 97' ' ' GLY . . . . . . . . . . . . . . . 83.8 26.79 40.45 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.497 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 98' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -94.86 -40.5 9.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.911 0.386 . . . . 0.0 110.716 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 99' ' ' TRP . . . . . 0.525 ' CG ' ' HG2' ' A' ' 67' ' ' PRO . 21.0 m95 -100.27 160.86 14.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.123 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 100' ' ' CYS . . . . . 0.406 ' N ' ' O ' ' C' ' 111' ' ' VAL . 6.6 m -142.25 116.09 9.26 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.39 179.578 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 101' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -80.08 108.61 13.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.868 0.366 . . . . 0.0 110.957 -179.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 102' ' ' ALA . . . . . . . . . . . . . . . -100.93 154.53 18.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.13 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 103' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -142.1 137.9 31.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.803 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 104' ' ' THR . . . . . . . . . . . . . 3.4 p -141.7 -169.11 2.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.112 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 105' ' ' LYS . . . . . . . . . . . . . 29.7 pttt -59.6 -25.54 64.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.909 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 106' ' ' ASN . . . . . . . . . . . . . 23.6 t30 -81.19 -28.96 34.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.891 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 107' ' ' GLY . . . . . . . . . . . . . . . 142.37 -157.62 26.64 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.537 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 108' ' ' GLN . . . . . . . . . . . . . 27.1 mt-30 -95.43 164.2 12.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 110.914 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 109' ' ' GLY . . . . . 0.415 ' HA3' ' CB ' ' C' ' 80' ' ' LEU . . . -169.03 155.87 26.67 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.569 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 110' ' ' TRP . . . . . 0.493 ' CD1' ' HB3' ' C' ' 78' ' ' ASN . 40.9 m95 -98.65 109.53 22.27 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.951 0.405 . . . . 0.0 111.009 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 111' ' ' VAL . . . . . 0.416 HG21 ' CG2' ' C' ' 116' ' ' ILE . 26.9 m -114.24 141.22 26.07 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.779 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 112' ' ' PRO . . . . . 0.431 ' HB3' ' CG2' ' A' ' 71' ' ' VAL . 74.7 Cg_exo -49.94 163.62 0.52 Allowed 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.522 2.148 . . . . 0.0 112.169 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 113' ' ' SER . . . . . . . . . . . . . 4.0 m -82.16 -20.55 37.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.404 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 114' ' ' ASN . . . . . 0.461 ' OD1' ' CD1' ' C' ' 115' ' ' TYR . 15.7 p30 -99.17 -42.48 7.03 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.75 0.309 . . . . 0.0 111.383 -179.631 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 115' ' ' TYR . . . . . 0.481 ' CE1' ' HG2' ' A' ' 72' ' ' PRO . 54.8 m-85 -59.48 -17.02 28.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.528 -179.65 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 116' ' ' ILE . . . . . 0.416 ' CG2' HG21 ' C' ' 111' ' ' VAL . 1.7 pp -116.83 157.83 17.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 120.796 0.332 . . . . 0.0 111.266 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 117' ' ' THR . . . . . 0.464 ' CG2' ' CD1' ' C' ' 69' ' ' LEU . 12.7 t -163.07 146.24 8.42 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.184 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 118' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -50.46 151.07 10.54 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.581 2.188 . . . . 0.0 112.27 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 119' ' ' VAL . . . . . . . . . . . . . 33.8 m -68.43 169.35 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.121 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 120' ' ' ASN . . . . . . . . . . . . . 13.8 m120 -70.44 110.43 5.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.904 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 121' ' ' SER . . . . . . . . . . . . . 4.6 p . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.249 -0.881 . . . . 0.0 110.883 179.992 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 120.786 0.327 . . . . 0.0 111.168 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.758 ' CE3' HD11 ' A' ' 101' ' ' LEU . 28.6 p-90 -92.53 -18.71 22.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.271 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' TYR . . . . . 0.442 ' HA ' ' CG1' ' A' ' 37' ' ' VAL . 2.7 t80 -83.4 96.0 8.41 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.864 0.364 . . . . 0.0 111.098 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' TRP . . . . . 0.664 ' CE3' HD13 ' A' ' 18' ' ' LEU . 39.1 m95 -100.58 110.04 22.16 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.629 179.745 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -98.67 132.96 11.13 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.635 -0.793 . . . . 0.0 112.749 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 73.75 26.06 1.9 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.785 0.326 . . . . 0.0 111.089 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.664 HD13 ' CE3' ' A' ' 15' ' ' TRP . 4.4 tp -81.56 115.04 20.67 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.933 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.07 146.3 53.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.913 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ARG . . . . . 0.46 ' HD3' ' P ' ' B' ' 221' ' ' PTR . 22.6 mtm180 -55.06 -50.92 67.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.853 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 -56.75 -32.13 65.27 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.883 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -69.83 -52.38 25.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.798 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.477 ' HB2' HD21 ' A' ' 18' ' ' LEU . . . -49.8 -56.22 11.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.013 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.7 HG22 HG11 ' A' ' 57' ' ' VAL . 57.8 t -56.1 -45.62 80.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.029 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -61.18 -21.28 63.65 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.428 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 30.1 mt -91.97 -43.47 9.43 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.971 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.608 HD22 ' CG2' ' A' ' 57' ' ' VAL . 7.5 mp -78.95 -23.51 44.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.995 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 1.7 tp60 -50.31 119.21 3.51 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.872 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.76 10.22 86.37 Favored Glycine 0 CA--C 1.52 0.381 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.911 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 85.3 mm-40 -90.48 129.23 36.67 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 121.067 0.46 . . . . 0.0 111.029 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.42 ' CD ' ' O ' ' A' ' 32' ' ' HIS . 0.0 OUTLIER -49.28 164.49 0.08 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.728 179.736 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 32' ' ' HIS . . . . . 0.42 ' O ' ' CD ' ' A' ' 31' ' ' ARG . 3.7 m170 -69.02 148.16 50.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.953 0.406 . . . . 0.0 111.262 -179.435 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 110.04 -18.51 28.58 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.535 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.598 ' CG2' HG12 ' A' ' 118' ' ' VAL . 14.9 p -80.06 123.79 37.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.787 0.327 . . . . 0.0 111.138 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.843 ' CG ' HD23 ' A' ' 114' ' ' LEU . 42.1 p90 -147.15 157.99 43.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.962 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.731 HD23 HG11 ' A' ' 118' ' ' VAL . 2.4 pp -165.31 150.55 9.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.022 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 1.007 HG21 HD21 ' A' ' 97' ' ' LEU . 10.5 p -91.49 147.04 5.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.833 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.406 ' HB2' ' HB3' ' A' ' 18' ' ' LEU . 41.8 ptt85 -152.55 147.43 26.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.019 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -70.74 129.5 39.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.829 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.0 t -63.94 152.27 40.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.895 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 50.8 m -85.01 -50.05 7.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.023 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.456 HG22 ' O2P' ' B' ' 221' ' ' PTR . 9.1 t -94.39 23.97 4.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.209 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.417 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . 0.8 OUTLIER -146.48 97.78 4.31 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.847 179.952 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.417 ' HD2' ' HA ' ' A' ' 43' ' ' SER . 38.2 Cg_endo -66.54 136.7 43.77 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.537 2.158 . . . . 0.0 112.292 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 60.56 33.68 82.81 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.439 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -129.02 132.94 47.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.814 0.34 . . . . 0.0 110.941 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.62 ' CE2' HD11 ' A' ' 97' ' ' LEU . 9.7 m-85 -92.56 168.32 11.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.803 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.603 HG13 ' O ' ' A' ' 60' ' ' TYR . 4.0 t -143.58 135.43 23.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.031 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.641 HD11 HD23 ' A' ' 101' ' ' LEU . 1.1 mm? -92.02 112.13 23.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.898 -179.82 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -94.51 138.32 32.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.793 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.442 HG12 ' HB3' ' A' ' 35' ' ' PHE . 3.1 m -151.37 121.36 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.08 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.602 ' N ' HD23 ' A' ' 27' ' ' LEU . 15.8 t -77.4 97.31 4.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.0 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.419 ' CG ' ' OG1' ' A' ' 111' ' ' THR . 0.0 OUTLIER -75.02 -160.31 0.11 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.834 179.844 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.416 ' O ' ' CB ' ' A' ' 55' ' ' SER . 7.0 p-10 -77.47 81.29 3.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.87 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.416 ' CB ' ' O ' ' A' ' 54' ' ' ASN . 0.7 OUTLIER 80.47 14.86 0.75 Allowed 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.326 -179.974 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -151.8 128.33 10.73 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.784 0.326 . . . . 0.0 110.765 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.7 HG11 HG22 ' A' ' 24' ' ' VAL . 14.1 p -95.97 113.28 29.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.239 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -87.66 160.28 18.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.76 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' HIS . . . . . . . . . . . . . 3.1 p80 -147.83 104.82 3.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.233 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.969 ' CE2' HD23 ' A' ' 109' ' ' LEU . 95.3 m-85 -86.42 145.21 26.94 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.453 179.539 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.558 HD12 ' CE1' ' B' ' 221' ' ' PTR . 2.3 tt -86.31 133.85 28.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.906 0.384 . . . . 0.0 111.613 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.795 HG13 HD13 ' A' ' 89' ' ' ILE . 5.2 mp -130.99 150.13 34.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.91 179.741 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -104.19 140.26 38.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.873 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.532 ' OG ' HD21 ' A' ' 87' ' ' LEU . 0.3 OUTLIER -144.61 146.11 32.13 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.019 -179.982 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 16.7 p -59.38 151.21 24.23 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.065 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -76.17 -85.38 0.38 Allowed Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.915 -0.659 . . . . 0.0 112.737 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.536 ' HG2' ' CG ' ' C' ' 99' ' ' TRP . 35.1 Cg_exo -57.76 164.17 8.12 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.583 2.189 . . . . 0.0 112.279 179.817 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.51 ' N ' ' CD ' ' A' ' 69' ' ' PRO . 0.0 OUTLIER -70.38 -46.99 19.78 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.104 178.867 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.566 ' HG2' HG23 ' C' ' 79' ' ' THR . 28.5 Cg_exo -58.21 136.36 74.18 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 122.323 2.015 . . . . 0.0 112.124 179.354 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -83.37 128.74 4.9 Favored 'Trans proline' 0 N--CA 1.453 -0.888 0 C-N-CA 122.153 1.902 . . . . 0.0 109.895 178.286 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.444 ' HA ' ' HD3' ' A' ' 72' ' ' PRO . 1.5 p -72.11 128.92 88.48 Favored Pre-proline 0 C--N 1.323 -0.544 0 C-N-CA 120.177 -0.609 . . . . 0.0 111.342 -178.706 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.472 ' HG2' ' CE1' ' C' ' 115' ' ' TYR . 11.7 Cg_endo -82.91 163.17 15.88 Favored 'Trans proline' 0 N--CA 1.455 -0.772 0 C-N-CA 122.345 2.03 . . . . 0.0 112.492 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -78.84 169.06 20.06 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.737 2.291 . . . . 0.0 112.597 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -95.43 169.1 9.78 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.833 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -49.77 164.09 0.43 Allowed 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.658 2.238 . . . . 0.0 112.33 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -53.24 -22.45 6.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.316 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 -69.74 174.6 2.94 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.642 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -48.52 122.32 7.66 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.388 2.059 . . . . 0.0 112.173 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.4 ' HB2' ' HB ' ' A' ' 82' ' ' VAL . 86.0 Cg_endo -86.6 118.69 1.57 Allowed 'Trans proline' 0 N--CA 1.461 -0.441 0 C-N-CA 122.638 2.225 . . . . 0.0 112.51 -179.825 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.29 128.8 10.73 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.421 2.08 . . . . 0.0 112.251 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 48.31 46.93 28.37 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.579 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.567 HG13 ' O ' ' A' ' 82' ' ' VAL . 13.5 p -63.06 117.18 3.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.891 0.376 . . . . 0.0 111.175 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 48.3 t -151.1 89.59 4.25 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.88 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.67 158.1 8.77 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.619 2.213 . . . . 0.0 112.326 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 13.1 m -96.58 1.2 51.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.712 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 1.4 mtt85 -52.06 169.06 0.08 Allowed 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.808 0.337 . . . . 0.0 110.918 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.607 HD12 HD23 ' A' ' 100' ' ' LEU . 0.2 OUTLIER -84.64 148.38 26.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.642 179.956 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -144.17 140.4 29.33 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.049 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.795 HD13 HG13 ' A' ' 62' ' ' ILE . 4.2 tp -156.99 115.89 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.975 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 59.95 -134.77 50.82 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.503 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 8.1 t0 -89.94 24.33 2.46 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 111.649 0.24 . . . . 0.0 111.649 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.0 150.62 30.19 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.874 0.369 . . . . 0.0 111.148 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.428 ' C ' ' CD1' ' A' ' 94' ' ' PHE . 2.2 mt-10 -112.95 167.12 10.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.73 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' PHE . . . . . 0.492 ' CE2' ' HB2' ' A' ' 103' ' ' PHE . 39.2 m-85 -146.96 166.13 27.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.056 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 27.4 t0 -75.07 -34.33 61.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.377 -179.569 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.437 ' CB ' ' HD2' ' A' ' 98' ' ' PRO . 35.0 t -166.83 -173.41 2.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.961 0.41 . . . . 0.0 111.303 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.007 HD21 HG21 ' A' ' 37' ' ' VAL . 0.6 OUTLIER -61.13 -48.35 92.28 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.17 -179.885 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.47 ' CD ' ' N ' ' A' ' 97' ' ' LEU . 71.1 Cg_exo -45.75 -49.61 10.63 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.245 1.963 . . . . 0.0 111.873 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.462 ' HB1' ' HD2' ' A' ' 94' ' ' PHE . . . -65.99 -38.82 89.49 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.576 179.469 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.607 HD23 HD12 ' A' ' 87' ' ' LEU . 0.0 OUTLIER -59.68 -60.46 3.8 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.999 179.59 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.758 HD11 ' CE3' ' A' ' 13' ' ' TRP . 16.2 mt -48.17 -44.02 32.13 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.964 179.531 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.663 ' O ' HD12 ' A' ' 106' ' ' ILE . 4.6 mt-10 -58.05 -41.7 83.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.623 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.492 ' HB2' ' CE2' ' A' ' 94' ' ' PHE . 14.2 t80 -58.24 -53.48 57.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.81 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' TYR . . . . . 0.609 ' CE2' HD22 ' A' ' 109' ' ' LEU . 3.0 m-85 -56.38 -32.85 65.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.821 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 4.5 ttpm? -77.32 -27.34 52.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.946 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.663 HD12 ' O ' ' A' ' 102' ' ' GLU . 5.3 mt -93.96 -21.81 5.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.388 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 9.1 t60 -96.02 173.83 7.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.885 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -108.61 45.86 1.0 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.952 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.969 HD23 ' CE2' ' A' ' 60' ' ' TYR . 0.3 OUTLIER -55.24 -69.41 0.13 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.648 179.867 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 16.1 p-10 -102.32 -176.95 3.26 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.466 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' THR . . . . . 0.593 ' O ' HG22 ' A' ' 112' ' ' THR . 18.2 m -46.64 125.05 6.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.028 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' THR . . . . . 0.593 HG22 ' O ' ' A' ' 111' ' ' THR . 12.5 t 47.45 -176.15 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.201 -179.409 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -97.23 159.96 14.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.123 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.843 HD23 ' CG ' ' A' ' 35' ' ' PHE . 5.8 mp -72.43 155.96 39.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.732 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 58.8 mt -114.23 -64.25 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.213 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -150.64 160.06 33.28 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.989 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' PRO . . . . . 0.424 ' HB3' ' HB3' ' A' ' 13' ' ' TRP . 55.7 Cg_endo -69.99 159.01 54.76 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.583 2.189 . . . . 0.0 112.306 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.731 HG11 HD23 ' A' ' 36' ' ' LEU . 17.1 m -49.9 -29.92 5.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.143 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -79.03 -179.12 6.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.919 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 7.9 mtm180 . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.27 -0.871 . . . . 0.0 110.894 179.997 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 217' ' ' GLU . . . . . 0.47 ' CB ' ' CD ' ' B' ' 218' ' ' PRO . 4.4 mp0 . . . . . 0 N--CA 1.487 1.424 0 CA-C-O 120.68 0.276 . . . . 0.0 111.225 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 218' ' ' PRO . . . . . 0.47 ' CD ' ' CB ' ' B' ' 217' ' ' GLU . 67.3 Cg_endo -74.35 63.25 5.37 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.591 2.194 . . . . 0.0 112.327 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 219' ' ' GLY . . . . . . . . . . . . . . . -128.14 59.8 0.68 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.485 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 220' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -70.89 -32.44 13.88 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.578 2.186 . . . . 0.0 112.332 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 221' ' ' PTR . . . . . 0.558 ' CE1' HD12 ' A' ' 61' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 222' ' ' ALA . . . . . . . . . . . . . . . -74.59 -61.54 1.84 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.143 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 223' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 69.82 95.24 0.05 OUTLIER Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.893 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 224' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -69.16 105.21 1.35 Allowed 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.566 2.177 . . . . 0.0 112.319 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 225' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -133.71 -46.51 0.8 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.904 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 226' ' ' VAL . . . . . . . . . . . . . 43.1 t 53.63 71.3 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.145 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 227' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -138.22 -74.76 0.39 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.905 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 12.1 p 53.34 -170.68 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.136 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 229' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.226 -0.893 . . . . 0.0 110.877 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 62' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.762 0.315 . . . . 0.0 111.204 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 63' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_exo -51.9 -39.62 68.28 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.559 2.173 . . . . 0.0 112.284 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 64' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -176.91 40.61 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.924 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 65' ' ' LEU . . . . . 0.686 HD23 HG21 ' C' ' 119' ' ' VAL . 4.8 tp -121.25 108.34 13.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.855 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 66' ' ' PHE . . . . . 0.644 ' HB2' HG23 ' C' ' 90' ' ' VAL . 29.4 m-85 -133.79 176.62 8.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 67' ' ' VAL . . . . . 0.701 HG23 ' O ' ' C' ' 86' ' ' GLU . 14.9 p -154.32 143.14 13.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.301 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 68' ' ' ALA . . . . . 0.41 ' HA ' ' HA ' ' C' ' 116' ' ' ILE . . . -86.12 137.07 32.94 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.041 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 69' ' ' LEU . . . . . 0.862 HD11 HG22 ' C' ' 117' ' ' THR . 4.3 mp -85.53 -29.77 23.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.957 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 70' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -128.95 174.04 9.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.788 -179.823 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 71' ' ' ASP . . . . . 0.428 ' N ' ' HB3' ' C' ' 84' ' ' LYS . 9.6 p-10 -89.36 109.8 20.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.903 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 72' ' ' PHE . . . . . 0.434 ' HB3' ' CG1' ' C' ' 82' ' ' ILE . 25.6 t80 -96.06 141.75 29.08 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.885 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 73' ' ' VAL . . . . . . . . . . . . . 56.1 t -118.63 134.58 61.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.144 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 74' ' ' ALA . . . . . 0.513 ' HB2' ' HB ' ' C' ' 79' ' ' THR . . . -118.98 147.93 43.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.067 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 75' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -98.22 26.97 4.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.944 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 76' ' ' GLY . . . . . . . . . . . . . . . 92.56 -25.02 20.45 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.512 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 77' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -57.31 -161.8 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.811 0.339 . . . . 0.0 110.859 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 78' ' ' ASN . . . . . 0.48 ' HB3' ' CD1' ' C' ' 110' ' ' TRP . 0.3 OUTLIER -50.39 -26.85 5.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.881 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' C' C ' 79' ' ' THR . . . . . 0.655 HG22 ' O ' ' C' ' 110' ' ' TRP . 0.6 OUTLIER -75.49 163.4 27.43 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.646 -179.963 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' C' C ' 80' ' ' LEU . . . . . 0.464 ' O ' HG23 ' C' ' 82' ' ' ILE . 1.9 tp -135.22 119.36 17.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.668 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 81' ' ' SER . . . . . 0.467 ' N ' ' HB3' ' C' ' 74' ' ' ALA . 49.1 p -55.02 114.87 1.92 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.061 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 82' ' ' ILE . . . . . 0.464 HG23 ' O ' ' C' ' 80' ' ' LEU . 5.9 pt -134.32 150.52 30.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.157 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 83' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -89.15 -179.62 5.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.181 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 84' ' ' LYS . . . . . 0.428 ' HB3' ' N ' ' C' ' 71' ' ' ASP . 7.7 ptpp? -91.1 149.91 21.61 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.968 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 85' ' ' GLY . . . . . . . . . . . . . . . 71.48 12.23 73.06 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.94 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 86' ' ' GLU . . . . . 0.701 ' O ' HG23 ' C' ' 67' ' ' VAL . 3.7 tp10 -91.04 145.01 25.05 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.8 0.334 . . . . 0.0 110.837 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 87' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -93.98 125.7 38.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.809 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -128.41 154.63 45.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.957 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 89' ' ' ARG . . . . . . . . . . . . . 2.5 mtt-85 -96.85 101.94 13.62 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.739 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 90' ' ' VAL . . . . . 0.644 HG23 ' HB2' ' C' ' 66' ' ' PHE . 57.1 t -84.48 107.57 15.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.3 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 91' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -118.74 19.06 13.27 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.083 179.77 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 92' ' ' GLY . . . . . . . . . . . . . . . -155.18 141.2 7.92 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.676 -0.774 . . . . 0.0 112.524 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 93' ' ' TYR . . . . . . . . . . . . . 59.2 m-85 -131.34 173.12 11.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.808 0.337 . . . . 0.0 110.925 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 94' ' ' ASN . . . . . . . . . . . . . 20.0 t-20 -98.75 164.88 12.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.912 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 95' ' ' HIS . . . . . . . . . . . . . 81.9 t60 -67.63 -25.23 65.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.94 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 96' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -103.44 -15.3 15.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.379 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 97' ' ' GLY . . . . . . . . . . . . . . . 83.8 26.79 40.45 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.497 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 98' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -94.86 -40.5 9.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.911 0.386 . . . . 0.0 110.716 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 99' ' ' TRP . . . . . 0.536 ' CG ' ' HG2' ' A' ' 67' ' ' PRO . 21.0 m95 -100.27 160.86 14.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.123 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 100' ' ' CYS . . . . . 0.606 ' O ' HG22 ' C' ' 111' ' ' VAL . 6.6 m -142.25 116.09 9.26 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.39 179.578 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 101' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -80.08 108.61 13.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.868 0.366 . . . . 0.0 110.957 -179.63 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 102' ' ' ALA . . . . . 0.41 ' HA ' ' HA ' ' C' ' 90' ' ' VAL . . . -100.93 154.53 18.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.13 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 103' ' ' GLN . . . . . . . . . . . . . 6.6 tm0? -142.1 137.9 31.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.803 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 104' ' ' THR . . . . . . . . . . . . . 3.4 p -141.7 -169.11 2.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.112 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 105' ' ' LYS . . . . . . . . . . . . . 29.7 pttt -59.6 -25.54 64.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.909 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 106' ' ' ASN . . . . . . . . . . . . . 23.6 t30 -81.19 -28.96 34.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.891 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 107' ' ' GLY . . . . . . . . . . . . . . . 142.37 -157.62 26.64 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.537 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 108' ' ' GLN . . . . . . . . . . . . . 43.9 mt-30 -95.43 164.2 12.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 110.914 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 109' ' ' GLY . . . . . 0.435 ' HA3' ' CB ' ' C' ' 80' ' ' LEU . . . -169.03 155.87 26.67 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.569 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 110' ' ' TRP . . . . . 0.655 ' O ' HG22 ' C' ' 79' ' ' THR . 40.9 m95 -98.65 109.53 22.27 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.951 0.405 . . . . 0.0 111.009 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 111' ' ' VAL . . . . . 0.793 ' CG2' HG21 ' C' ' 116' ' ' ILE . 26.9 m -114.24 141.22 26.07 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.779 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 112' ' ' PRO . . . . . 0.445 ' HG3' ' HD2' ' A' ' 72' ' ' PRO . 74.7 Cg_exo -49.94 163.62 0.52 Allowed 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.522 2.148 . . . . 0.0 112.169 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 113' ' ' SER . . . . . . . . . . . . . 4.0 m -82.16 -20.55 37.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.404 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 114' ' ' ASN . . . . . 0.461 ' OD1' ' CD1' ' C' ' 115' ' ' TYR . 15.7 p30 -99.17 -42.48 7.03 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.75 0.309 . . . . 0.0 111.383 -179.631 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 115' ' ' TYR . . . . . 0.472 ' CE1' ' HG2' ' A' ' 72' ' ' PRO . 54.8 m-85 -59.48 -17.02 28.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.528 -179.65 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 116' ' ' ILE . . . . . 0.793 HG21 ' CG2' ' C' ' 111' ' ' VAL . 1.7 pp -116.83 157.83 17.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 120.796 0.332 . . . . 0.0 111.266 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 117' ' ' THR . . . . . 0.862 HG22 HD11 ' C' ' 69' ' ' LEU . 12.7 t -163.07 146.24 8.42 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.184 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 118' ' ' PRO . . . . . 0.457 ' HA ' ' HA ' ' C' ' 66' ' ' PHE . 76.5 Cg_exo -50.46 151.07 10.54 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.581 2.188 . . . . 0.0 112.27 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 119' ' ' VAL . . . . . 0.686 HG21 HD23 ' C' ' 65' ' ' LEU . 33.8 m -68.43 169.35 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.121 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 120' ' ' ASN . . . . . . . . . . . . . 13.8 m120 -70.44 110.43 5.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.904 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 121' ' ' SER . . . . . . . . . . . . . 4.6 p . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.249 -0.881 . . . . 0.0 110.883 179.992 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 120.786 0.327 . . . . 0.0 111.168 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.758 ' CE3' HD11 ' A' ' 101' ' ' LEU . 28.6 p-90 -92.53 -18.71 22.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.271 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . 0.442 ' HA ' ' CG1' ' A' ' 37' ' ' VAL . 2.7 t80 -83.4 96.0 8.41 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.864 0.364 . . . . 0.0 111.098 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' TRP . . . . . 0.664 ' CE3' HD13 ' A' ' 18' ' ' LEU . 39.1 m95 -100.58 110.04 22.16 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.629 179.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -98.67 132.96 11.13 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.635 -0.793 . . . . 0.0 112.749 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 73.75 26.06 1.9 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.785 0.326 . . . . 0.0 111.089 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.664 HD13 ' CE3' ' A' ' 15' ' ' TRP . 4.4 tp -81.56 115.04 20.67 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.933 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.07 146.3 53.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.913 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . 0.46 ' HD3' ' P ' ' B' ' 221' ' ' PTR . 22.6 mtm180 -55.06 -50.92 67.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.853 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 -56.75 -32.13 65.27 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.883 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -69.83 -52.38 25.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.798 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.477 ' HB2' HD21 ' A' ' 18' ' ' LEU . . . -49.8 -56.22 11.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.013 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.7 HG22 HG11 ' A' ' 57' ' ' VAL . 57.8 t -56.1 -45.62 80.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.029 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -61.18 -21.28 63.65 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.428 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 30.1 mt -91.97 -43.47 9.43 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.971 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.608 HD22 ' CG2' ' A' ' 57' ' ' VAL . 7.5 mp -78.95 -23.51 44.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.995 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 1.7 tp60 -50.31 119.21 3.51 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.872 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.76 10.22 86.37 Favored Glycine 0 CA--C 1.52 0.381 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.911 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 85.3 mm-40 -90.48 129.23 36.67 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 121.067 0.46 . . . . 0.0 111.029 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.42 ' CD ' ' O ' ' A' ' 32' ' ' HIS . 0.0 OUTLIER -49.28 164.49 0.08 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.728 179.736 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' HIS . . . . . 0.42 ' O ' ' CD ' ' A' ' 31' ' ' ARG . 3.7 m170 -69.02 148.16 50.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.953 0.406 . . . . 0.0 111.262 -179.435 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 110.04 -18.51 28.58 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.535 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.598 ' CG2' HG12 ' A' ' 118' ' ' VAL . 14.9 p -80.06 123.79 37.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.787 0.327 . . . . 0.0 111.138 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.843 ' CG ' HD23 ' A' ' 114' ' ' LEU . 42.1 p90 -147.15 157.99 43.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.962 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.731 HD23 HG11 ' A' ' 118' ' ' VAL . 2.4 pp -165.31 150.55 9.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.022 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 1.007 HG21 HD21 ' A' ' 97' ' ' LEU . 10.5 p -91.49 147.04 5.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.833 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.406 ' HB2' ' HB3' ' A' ' 18' ' ' LEU . 41.8 ptt85 -152.55 147.43 26.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.019 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -70.74 129.5 39.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.829 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.0 t -63.94 152.27 40.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.895 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 50.8 m -85.01 -50.05 7.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.023 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.456 HG22 ' O2P' ' B' ' 221' ' ' PTR . 9.1 t -94.39 23.97 4.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.209 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.417 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . 0.8 OUTLIER -146.48 97.78 4.31 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.847 179.952 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.417 ' HD2' ' HA ' ' A' ' 43' ' ' SER . 38.2 Cg_endo -66.54 136.7 43.77 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.537 2.158 . . . . 0.0 112.292 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 60.56 33.68 82.81 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.439 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -129.02 132.94 47.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.814 0.34 . . . . 0.0 110.941 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.62 ' CE2' HD11 ' A' ' 97' ' ' LEU . 9.7 m-85 -92.56 168.32 11.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.803 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.603 HG13 ' O ' ' A' ' 60' ' ' TYR . 4.0 t -143.58 135.43 23.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.031 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.641 HD11 HD23 ' A' ' 101' ' ' LEU . 1.1 mm? -92.02 112.13 23.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.898 -179.82 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -94.51 138.32 32.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.793 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.442 HG12 ' HB3' ' A' ' 35' ' ' PHE . 3.1 m -151.37 121.36 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.08 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.602 ' N ' HD23 ' A' ' 27' ' ' LEU . 15.8 t -77.4 97.31 4.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.0 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.419 ' CG ' ' OG1' ' A' ' 111' ' ' THR . 0.0 OUTLIER -75.02 -160.31 0.11 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.834 179.844 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.416 ' O ' ' CB ' ' A' ' 55' ' ' SER . 7.0 p-10 -77.47 81.29 3.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.87 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.416 ' CB ' ' O ' ' A' ' 54' ' ' ASN . 0.7 OUTLIER 80.47 14.86 0.75 Allowed 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.326 -179.974 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -151.8 128.33 10.73 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.784 0.326 . . . . 0.0 110.765 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.7 HG11 HG22 ' A' ' 24' ' ' VAL . 14.1 p -95.97 113.28 29.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.239 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -87.66 160.28 18.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.76 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' HIS . . . . . . . . . . . . . 3.1 p80 -147.83 104.82 3.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.233 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.969 ' CE2' HD23 ' A' ' 109' ' ' LEU . 95.3 m-85 -86.42 145.21 26.94 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.453 179.539 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.558 HD12 ' CE1' ' B' ' 221' ' ' PTR . 2.3 tt -86.31 133.85 28.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.906 0.384 . . . . 0.0 111.613 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.795 HG13 HD13 ' A' ' 89' ' ' ILE . 5.2 mp -130.99 150.13 34.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.91 179.741 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -104.19 140.26 38.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.873 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.532 ' OG ' HD21 ' A' ' 87' ' ' LEU . 0.3 OUTLIER -144.61 146.11 32.13 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.019 -179.982 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 16.7 p -59.38 151.21 24.23 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.065 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -76.17 -85.38 0.38 Allowed Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.915 -0.659 . . . . 0.0 112.737 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.536 ' HG2' ' CG ' ' C' ' 99' ' ' TRP . 35.1 Cg_exo -57.76 164.17 8.12 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.583 2.189 . . . . 0.0 112.279 179.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.51 ' N ' ' CD ' ' A' ' 69' ' ' PRO . 0.0 OUTLIER -70.38 -46.99 19.78 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.104 178.867 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.566 ' HG2' HG23 ' C' ' 79' ' ' THR . 28.5 Cg_exo -58.21 136.36 74.18 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 122.323 2.015 . . . . 0.0 112.124 179.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -83.37 128.74 4.9 Favored 'Trans proline' 0 N--CA 1.453 -0.888 0 C-N-CA 122.153 1.902 . . . . 0.0 109.895 178.286 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.444 ' HA ' ' HD3' ' A' ' 72' ' ' PRO . 1.5 p -72.11 128.92 88.48 Favored Pre-proline 0 C--N 1.323 -0.544 0 C-N-CA 120.177 -0.609 . . . . 0.0 111.342 -178.706 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.472 ' HG2' ' CE1' ' C' ' 115' ' ' TYR . 11.7 Cg_endo -82.91 163.17 15.88 Favored 'Trans proline' 0 N--CA 1.455 -0.772 0 C-N-CA 122.345 2.03 . . . . 0.0 112.492 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -78.84 169.06 20.06 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.737 2.291 . . . . 0.0 112.597 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -95.43 169.1 9.78 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.833 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -49.77 164.09 0.43 Allowed 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.658 2.238 . . . . 0.0 112.33 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -53.24 -22.45 6.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.316 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 -69.74 174.6 2.94 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.642 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -48.52 122.32 7.66 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.388 2.059 . . . . 0.0 112.173 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.4 ' HB2' ' HB ' ' A' ' 82' ' ' VAL . 86.0 Cg_endo -86.6 118.69 1.57 Allowed 'Trans proline' 0 N--CA 1.461 -0.441 0 C-N-CA 122.638 2.225 . . . . 0.0 112.51 -179.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.29 128.8 10.73 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.421 2.08 . . . . 0.0 112.251 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 48.31 46.93 28.37 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.579 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.567 HG13 ' O ' ' A' ' 82' ' ' VAL . 13.5 p -63.06 117.18 3.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.891 0.376 . . . . 0.0 111.175 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 48.3 t -151.1 89.59 4.25 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.88 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.67 158.1 8.77 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.619 2.213 . . . . 0.0 112.326 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 13.1 m -96.58 1.2 51.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.712 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 1.4 mtt85 -52.06 169.06 0.08 Allowed 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.808 0.337 . . . . 0.0 110.918 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.607 HD12 HD23 ' A' ' 100' ' ' LEU . 0.2 OUTLIER -84.64 148.38 26.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.642 179.956 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -144.17 140.4 29.33 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.049 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.795 HD13 HG13 ' A' ' 62' ' ' ILE . 4.2 tp -156.99 115.89 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.975 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 59.95 -134.77 50.82 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.503 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 8.1 t0 -89.94 24.33 2.46 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 111.649 0.24 . . . . 0.0 111.649 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.0 150.62 30.19 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.874 0.369 . . . . 0.0 111.148 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.428 ' C ' ' CD1' ' A' ' 94' ' ' PHE . 2.2 mt-10 -112.95 167.12 10.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.73 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . 0.492 ' CE2' ' HB2' ' A' ' 103' ' ' PHE . 39.2 m-85 -146.96 166.13 27.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.056 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 27.4 t0 -75.07 -34.33 61.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.377 -179.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.437 ' CB ' ' HD2' ' A' ' 98' ' ' PRO . 35.0 t -166.83 -173.41 2.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.961 0.41 . . . . 0.0 111.303 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.007 HD21 HG21 ' A' ' 37' ' ' VAL . 0.6 OUTLIER -61.13 -48.35 92.28 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.17 -179.885 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.47 ' CD ' ' N ' ' A' ' 97' ' ' LEU . 71.1 Cg_exo -45.75 -49.61 10.63 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.245 1.963 . . . . 0.0 111.873 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.462 ' HB1' ' HD2' ' A' ' 94' ' ' PHE . . . -65.99 -38.82 89.49 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.576 179.469 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.607 HD23 HD12 ' A' ' 87' ' ' LEU . 0.0 OUTLIER -59.68 -60.46 3.8 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.999 179.59 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.758 HD11 ' CE3' ' A' ' 13' ' ' TRP . 16.2 mt -48.17 -44.02 32.13 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.964 179.531 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.663 ' O ' HD12 ' A' ' 106' ' ' ILE . 4.6 mt-10 -58.05 -41.7 83.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.623 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.492 ' HB2' ' CE2' ' A' ' 94' ' ' PHE . 14.2 t80 -58.24 -53.48 57.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.81 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . 0.609 ' CE2' HD22 ' A' ' 109' ' ' LEU . 3.0 m-85 -56.38 -32.85 65.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.821 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 4.5 ttpm? -77.32 -27.34 52.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.946 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.663 HD12 ' O ' ' A' ' 102' ' ' GLU . 5.3 mt -93.96 -21.81 5.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.388 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 9.1 t60 -96.02 173.83 7.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.885 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -108.61 45.86 1.0 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.952 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.969 HD23 ' CE2' ' A' ' 60' ' ' TYR . 0.3 OUTLIER -55.24 -69.41 0.13 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.648 179.867 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 16.1 p-10 -102.32 -176.95 3.26 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.466 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . 0.593 ' O ' HG22 ' A' ' 112' ' ' THR . 18.2 m -46.64 125.05 6.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.028 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . 0.593 HG22 ' O ' ' A' ' 111' ' ' THR . 12.5 t 47.45 -176.15 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.201 -179.409 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -97.23 159.96 14.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.123 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.843 HD23 ' CG ' ' A' ' 35' ' ' PHE . 5.8 mp -72.43 155.96 39.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.732 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ILE . . . . . . . . . . . . . 58.8 mt -114.23 -64.25 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.213 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -150.64 160.06 33.28 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.989 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . 0.424 ' HB3' ' HB3' ' A' ' 13' ' ' TRP . 55.7 Cg_endo -69.99 159.01 54.76 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.583 2.189 . . . . 0.0 112.306 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.731 HG11 HD23 ' A' ' 36' ' ' LEU . 17.1 m -49.9 -29.92 5.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.143 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -79.03 -179.12 6.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.919 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 7.9 mtm180 . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.27 -0.871 . . . . 0.0 110.894 179.997 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . 0.47 ' CB ' ' CD ' ' B' ' 218' ' ' PRO . 4.4 mp0 . . . . . 0 N--CA 1.487 1.424 0 CA-C-O 120.68 0.276 . . . . 0.0 111.225 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 218' ' ' PRO . . . . . 0.47 ' CD ' ' CB ' ' B' ' 217' ' ' GLU . 67.3 Cg_endo -74.35 63.25 5.37 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.591 2.194 . . . . 0.0 112.327 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 219' ' ' GLY . . . . . . . . . . . . . . . -128.14 59.8 0.68 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.485 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 220' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -70.89 -32.44 13.88 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.578 2.186 . . . . 0.0 112.332 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 221' ' ' PTR . . . . . 0.558 ' CE1' HD12 ' A' ' 61' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 222' ' ' ALA . . . . . . . . . . . . . . . -74.59 -61.54 1.84 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.143 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 223' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 69.82 95.24 0.05 OUTLIER Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.893 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 224' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -69.16 105.21 1.35 Allowed 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.566 2.177 . . . . 0.0 112.319 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 225' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -133.71 -46.51 0.8 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.904 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 226' ' ' VAL . . . . . . . . . . . . . 43.1 t 53.63 71.3 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.145 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 227' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -138.22 -74.76 0.39 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.905 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . . . . . . . . . 12.1 p 53.34 -170.68 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.136 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 229' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.226 -0.893 . . . . 0.0 110.877 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 62' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.762 0.315 . . . . 0.0 111.204 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 63' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_exo -51.9 -39.62 68.28 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.559 2.173 . . . . 0.0 112.284 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 64' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -176.91 40.61 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.924 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 65' ' ' LEU . . . . . 0.686 HD23 HG21 ' C' ' 119' ' ' VAL . 4.8 tp -121.25 108.34 13.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.855 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 66' ' ' PHE . . . . . 0.644 ' HB2' HG23 ' C' ' 90' ' ' VAL . 29.4 m-85 -133.79 176.62 8.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 67' ' ' VAL . . . . . 0.701 HG23 ' O ' ' C' ' 86' ' ' GLU . 14.9 p -154.32 143.14 13.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.301 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 68' ' ' ALA . . . . . 0.41 ' HA ' ' HA ' ' C' ' 116' ' ' ILE . . . -86.12 137.07 32.94 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.041 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 69' ' ' LEU . . . . . 0.862 HD11 HG22 ' C' ' 117' ' ' THR . 4.3 mp -85.53 -29.77 23.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.957 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 70' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -128.95 174.04 9.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.788 -179.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 71' ' ' ASP . . . . . 0.428 ' N ' ' HB3' ' C' ' 84' ' ' LYS . 9.6 p-10 -89.36 109.8 20.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.903 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 72' ' ' PHE . . . . . 0.434 ' HB3' ' CG1' ' C' ' 82' ' ' ILE . 25.6 t80 -96.06 141.75 29.08 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.885 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 73' ' ' VAL . . . . . . . . . . . . . 56.1 t -118.63 134.58 61.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.144 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 74' ' ' ALA . . . . . 0.513 ' HB2' ' HB ' ' C' ' 79' ' ' THR . . . -118.98 147.93 43.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.067 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 75' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -98.22 26.97 4.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.944 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 76' ' ' GLY . . . . . . . . . . . . . . . 92.56 -25.02 20.45 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.512 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 77' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -57.31 -161.8 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.811 0.339 . . . . 0.0 110.859 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 78' ' ' ASN . . . . . 0.48 ' HB3' ' CD1' ' C' ' 110' ' ' TRP . 0.3 OUTLIER -50.39 -26.85 5.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.881 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' C' C ' 79' ' ' THR . . . . . 0.655 HG22 ' O ' ' C' ' 110' ' ' TRP . 0.6 OUTLIER -75.49 163.4 27.43 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.646 -179.963 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' C' C ' 80' ' ' LEU . . . . . 0.464 ' O ' HG23 ' C' ' 82' ' ' ILE . 1.9 tp -135.22 119.36 17.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.668 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 81' ' ' SER . . . . . 0.467 ' N ' ' HB3' ' C' ' 74' ' ' ALA . 49.1 p -55.02 114.87 1.92 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.061 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 82' ' ' ILE . . . . . 0.464 HG23 ' O ' ' C' ' 80' ' ' LEU . 5.9 pt -134.32 150.52 30.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.157 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 83' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -89.15 -179.62 5.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.181 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 84' ' ' LYS . . . . . 0.428 ' HB3' ' N ' ' C' ' 71' ' ' ASP . 7.7 ptpp? -91.1 149.91 21.61 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.968 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 85' ' ' GLY . . . . . . . . . . . . . . . 71.48 12.23 73.06 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.94 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 86' ' ' GLU . . . . . 0.701 ' O ' HG23 ' C' ' 67' ' ' VAL . 3.7 tp10 -91.04 145.01 25.05 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.8 0.334 . . . . 0.0 110.837 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 87' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -93.98 125.7 38.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.809 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -128.41 154.63 45.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.957 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 89' ' ' ARG . . . . . . . . . . . . . 2.5 mtt-85 -96.85 101.94 13.62 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.739 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 90' ' ' VAL . . . . . 0.644 HG23 ' HB2' ' C' ' 66' ' ' PHE . 57.1 t -84.48 107.57 15.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.3 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 91' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -118.74 19.06 13.27 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.083 179.77 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 92' ' ' GLY . . . . . . . . . . . . . . . -155.18 141.2 7.92 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.676 -0.774 . . . . 0.0 112.524 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 93' ' ' TYR . . . . . . . . . . . . . 59.2 m-85 -131.34 173.12 11.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.808 0.337 . . . . 0.0 110.925 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 94' ' ' ASN . . . . . . . . . . . . . 20.0 t-20 -98.75 164.88 12.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.912 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 95' ' ' HIS . . . . . . . . . . . . . 81.9 t60 -67.63 -25.23 65.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.94 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 96' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -103.44 -15.3 15.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.379 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 97' ' ' GLY . . . . . . . . . . . . . . . 83.8 26.79 40.45 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.497 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 98' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -94.86 -40.5 9.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.911 0.386 . . . . 0.0 110.716 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 99' ' ' TRP . . . . . 0.536 ' CG ' ' HG2' ' A' ' 67' ' ' PRO . 21.0 m95 -100.27 160.86 14.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.123 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 100' ' ' CYS . . . . . 0.606 ' O ' HG22 ' C' ' 111' ' ' VAL . 6.6 m -142.25 116.09 9.26 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.39 179.578 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 101' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -80.08 108.61 13.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.868 0.366 . . . . 0.0 110.957 -179.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 102' ' ' ALA . . . . . 0.41 ' HA ' ' HA ' ' C' ' 90' ' ' VAL . . . -100.93 154.53 18.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.13 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 103' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -142.1 137.9 31.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.803 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 104' ' ' THR . . . . . . . . . . . . . 3.4 p -141.7 -169.11 2.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.112 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 105' ' ' LYS . . . . . . . . . . . . . 29.7 pttt -59.6 -25.54 64.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.909 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 106' ' ' ASN . . . . . . . . . . . . . 23.6 t30 -81.19 -28.96 34.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.891 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 107' ' ' GLY . . . . . . . . . . . . . . . 142.37 -157.62 26.64 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.537 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 108' ' ' GLN . . . . . . . . . . . . . 27.1 mt-30 -95.43 164.2 12.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 110.914 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 109' ' ' GLY . . . . . 0.435 ' HA3' ' CB ' ' C' ' 80' ' ' LEU . . . -169.03 155.87 26.67 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.569 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 110' ' ' TRP . . . . . 0.655 ' O ' HG22 ' C' ' 79' ' ' THR . 40.9 m95 -98.65 109.53 22.27 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.951 0.405 . . . . 0.0 111.009 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 111' ' ' VAL . . . . . 0.793 ' CG2' HG21 ' C' ' 116' ' ' ILE . 26.9 m -114.24 141.22 26.07 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.779 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 112' ' ' PRO . . . . . 0.445 ' HG3' ' HD2' ' A' ' 72' ' ' PRO . 74.7 Cg_exo -49.94 163.62 0.52 Allowed 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.522 2.148 . . . . 0.0 112.169 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 113' ' ' SER . . . . . . . . . . . . . 4.0 m -82.16 -20.55 37.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.404 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 114' ' ' ASN . . . . . 0.461 ' OD1' ' CD1' ' C' ' 115' ' ' TYR . 15.7 p30 -99.17 -42.48 7.03 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.75 0.309 . . . . 0.0 111.383 -179.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 115' ' ' TYR . . . . . 0.472 ' CE1' ' HG2' ' A' ' 72' ' ' PRO . 54.8 m-85 -59.48 -17.02 28.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.528 -179.65 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 116' ' ' ILE . . . . . 0.793 HG21 ' CG2' ' C' ' 111' ' ' VAL . 1.7 pp -116.83 157.83 17.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 120.796 0.332 . . . . 0.0 111.266 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 117' ' ' THR . . . . . 0.862 HG22 HD11 ' C' ' 69' ' ' LEU . 12.7 t -163.07 146.24 8.42 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.184 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 118' ' ' PRO . . . . . 0.457 ' HA ' ' HA ' ' C' ' 66' ' ' PHE . 76.5 Cg_exo -50.46 151.07 10.54 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.581 2.188 . . . . 0.0 112.27 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 119' ' ' VAL . . . . . 0.686 HG21 HD23 ' C' ' 65' ' ' LEU . 33.8 m -68.43 169.35 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.121 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 120' ' ' ASN . . . . . . . . . . . . . 13.8 m120 -70.44 110.43 5.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.904 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 121' ' ' SER . . . . . . . . . . . . . 4.6 p . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.249 -0.881 . . . . 0.0 110.883 179.992 . . . . . . . . 0 0 . 1 stop_ save_